ALLBC: A phase II a, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the humanized anti-CD19 antibody MOR00208 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)


Leukemias / Lymphomas : Relapsed or refractory B-cell acute lymphoblastic leukemia


The drug investigated in this study is called MOR00208. It is an investigational drug which is being developed to slow down the spread of tumor cells by using a new way to kill them.

MOR00208 is a monoclonal antibody which is a type of immunotherapy. It uses specific antibodies to destroy cancer cells. This type of therapy relies on the body’s own immune system to fight the cancer, rather than attacking the cells with chemotherapy or radiation. Antigens are cell surface markers that are produced in every type of cell of the body and also in bacteria and viruses. These markers are different in every cell type, so the body can identify them. Antibodies are designed to bind to antigens, like fitting two puzzle pieces together. Monoclonal antibodies are large groups of antibodies that only bind to one type of antigen. The study drug MOR00208 is a monoclonal antibody that binds to the human surface antigen CD19. The study drug is being tested in the treatment of B-cell acute lymphoblastic leukemia.




Eligibility criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Wing Leung, MD, PhD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.